Uncertainties surrounding the U.S. pharmaceutical sector and the turbulent development in global stock markets have led to ...

BB Biotech reported a net loss of CHF 241 mn for Q1 2025. The share price closed the quarter at a 14.1% discount to NAV, broadly in line with year-end 2024. The share price performance for the quarter ...

Over the last year, 89bio’s stock has been somewhat volatile. Shares climbed past $10 earlier this year, but dropped under $6 ...

This article summarizes the most significant insider buys and sells for US stocks reported on Friday, April 11, 2025.

NEW YORK CITY, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Analyst Price Forecast Suggests 35.52% Upside As of April 2, 2025, the average one-year price target for Tempest Therapeutics is $9.69/share. The forecasts range from a low of $5.05 to a high of ...

Viking Therapeutics has multiple promising drugs in its portfolio that could generate billions in future revenue. Approval of VK2735 and VK2809 could lead to a surge in the stock's value.

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have been assigned an average recommendation of “Buy” from the nine ratings firms that are covering the company ...

Get the next trade alert free. Vera Therapeutics, Inc. VERA said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients ...

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...

Introduced in FY23, Lupin Digital Health marked the company’s foray into the fast-growing digital therapeutics space. Its Lyfe platform focuses on real-time monitoring of patients and offers ...